Abstract 862P
Background
Human papillomavirus-driven (HPV) oropharyngeal cancers (OPC) are treated with aggressive multimodality regimens, despite their usually favourable prognosis. Yet, ∼25% of cases will develop recurrent or distant metastasis. Clinical monitoring of tumour progression and treatment response is often insufficient to detect asymptomatic lesions, delaying salvage treatment and reducing chances of cure. Therefore, we are exploring the clinical utility of measuring circulating tumour HPV DNA (ctHPVDNA) in HPV-driven OPC patients to guide outcome stratification and improve disease monitoring.
Methods
ctHPV16DNA levels were measured in plasma samples from OPC patients and controls from South America and Europe using droplet digital PCR (ddPCR). HPV16E6 serology results and well-annotated lifestyle and clinical information were available, and findings were tested for associations between ctHPV16DNA status/levels and patient clinical information. All samples were part of the HEADSpAcE study, coordinated by the International Agency for Research on Cancer (IARC). Funding: INCa_16295 and EUH2020_825771.
Results
Baseline plasma samples from HPV-seropositive (n=75) and seronegative (n=26) OPC cases, and 57 HPV-seronegative controls (n=57) were tested, and we reached 100% specificity and an overall sensitivity of 92.0% (69/75) in detecting ctHPV16DNA in HPV16-seropositive cases. 10/11 patients with small volume disease (cT1/T2 N0) were positive for ctHPVctDNA, and increasing levels were observed according to N (p=0.01) and clinical stage (p=0.0029). Moreover, baseline detection of ctHPV16DNA was associated with a reduced risk of death (HR= 0.38; p=0.034) and disease relapse (HR= 0.2; p=0.028).
Conclusions
We showed a high accuracy of plasma ctHPVDNA detection by ddPCR in a case series of OPC from Europe and South America. ctHPV16DNA levels/status in baseline plasma were associated with disease volume, and a reduced risk of relapse and death, suggesting its use in patient outcome stratification. Next, we will test ctHPVDNA in post-treatment plasma samples as a potential tool for improving patient management through a more efficient monitoring of minimal residual disease during patient surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ana Carolina de Carvalho, International Agency for Research on Cancer.
Funding
Institut National Du Cancer (INCa, France) - European Union - Horizon 2020.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
922P - Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma
Presenter: Glenn Hanna
Session: Poster session 12
923P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic head & neck squamous cell carcinoma – subgroup analysis of the PEVOsq basket trial
Presenter: Christophe Le Tourneau
Session: Poster session 12
924P - Polyfunctional HPV16-Specific T cell responses in subjects receiving PDS0101 and pembrolizumab combination treatment for recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC)
Presenter: Kevin Harrington
Session: Poster session 12
925P - Treatment discontinuation of immune checkpoint blockade in patients with head and neck squamous cell carcinoma experiencing complete or nearly complete remission
Presenter: Konrad Klinghammer
Session: Poster session 12
926P - UK national real-world outcome data of first-line pembrolizumab treatment in head and neck squamous cell cancer (HNSCC)
Presenter: Ifigenia Vasiliadou
Session: Poster session 12
927P - Patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) treated with nivolumab (NIVO) in the first-line (1L) or later-line (2L+) settings in Germany: Updated results from the real-world HANNA study
Presenter: Boris Kubuschok
Session: Poster session 12
928P - Prognostic value of body composition and nutritional assessment in recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCHN) treated with immunotherapy (IO)
Presenter: Zara Vidales Sepulveda
Session: Poster session 12
930P - Platinum and taxane (PT) plus immunotherapy versus immunotherapy alone in patients with recurrent/metastatic (R/M) head and neck cancer (HNSCC)
Presenter: Marcelo Bonomi
Session: Poster session 12
931P - Early recurrence, time-to-recurrence, and recurrence patterns: Assessing their impact on survival outcomes in recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC) patients
Presenter: Pasvich Pitakpaiboonkul
Session: Poster session 12